RxDoctor Payments Data

Christopher Jarvis, MD

Family Medicine · Burlington, KSNPI 1508860479

Payments from drug & device makers

$5,640in general payments, 2019–2025

Across 366 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$977
  • Novo Nordisk$668
  • Otsuka America Pharmaceutical, Inc.$614
  • Lilly USA, LLC$538
  • Amgen$318
  • Sunovion Pharmaceuticals Inc.$181
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,626100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,640 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$11,498
Medicare patients
135
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$82,289
EliquisApixaban119$67,156
JanuviaSitagliptin Phosphate58$43,183
VraylarCariprazine Hcl25$37,350
TrulicityDulaglutide25$28,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$26,416
JardianceEmpagliflozin35$22,992
XareltoRivaroxaban36$20,927
Tresiba Flextouch U-200Insulin Degludec22$19,414
MyrbetriqMirabegron25$16,389
Breo ElliptaFluticasone/Vilanterol31$16,282
Tresiba Flextouch U-100Insulin Degludec31$16,253
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen415$16,161
Spiriva RespimatTiotropium Bromide22$15,197
RybelsusSemaglutide16$15,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$668$97,30594 claims
PfizerEliquis$95$67,156119 claims
AbbVieVraylar, Ubrelvy, Linzess$977$61,34656 claims
MerckJanuvia, Belsomra$139$53,57278 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$14$49,60986 claims
Boehringer IngelheimJardiance, Spiriva Respimat$171$38,18957 claims
Lilly USA, LLCTrulicity$538$28,15125 claims
Johnson & JohnsonXarelto$160$20,92736 claims
Astellas Pharma US IncMyrbetriq$38$16,38925 claims
AstraZenecaBreztri Aerosphere$88$13,51321 claims
NovartisEntresto$13$9,88014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Burlington

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →